Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gefitinib in First Relapse Glioblastoma
NCT00016991Phase 2Completed
- Sponsor
- Duke University
- Start
- Jun 2001
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of gefitinib in glioblastoma multiforme (GBM), sponsored by Duke University. Primary endpoint: Activity of ZD 1839. Started Jun 2001; status: completed.
02
Drugs
03
Conditions
glioblastoma multiforme (GBM)
Beyond the preview
Go deeper on NCT00016991.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00016991.